Double-Edged Sword Against Relentless Myeloma: Groundbreaking Combo Delivers New Hope!
In a stunning development for patients battling one of the most aggressive forms of multiple myeloma, a novel combination therapy is rewriting the rulebook. For those facing the grim prognosis of extramedullary disease (EMD), where cancer spreads beyond the bones, hope has often been in short supply. But new data signals a powerful shift.
- Unprecedented Response: An investigational duo, TALVEY® and TECVAYLI®, achieved a remarkable 78.9% overall response rate in heavily pretreated EMD patients3.
- Deep, Lasting Remissions: More than half (54.4%) of these patients saw a complete response or better, with many responses enduring over a year3.
- Challenging the Norm: This significantly surpasses the less than 40% response rates typically seen with standard therapies in this difficult-to-treat population2.
Johnson & Johnson recently unveiled these electrifying results from the Phase 2 RedirecTT-1 study at the 2025 European Hematology Association (EHA) Congress (Abstract )3. This study, the largest of its kind for EMD, pits two first-in-class bispecific antibodies against a relentless foe. TALVEY®, targeting GPRC5D, and TECVAYLI®, targeting BCMA, create a dual-pronged attack designed to outsmart the cancer's escape mechanisms1.
Patients with EMD face a daunting reality: tumors in soft tissues and organs, limited options, and rapid relapses1. "The investigational combination...has demonstrated deep, durable responses...where standard therapies often fall short," stated Dr. Yael Cohen, Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center. "Dual targeting...may lead to a higher ORR and greater depth of response."3
Remarkably, 61 percent of patients remained progression-free and alive at one year, with a median follow-up of 13.4 months signaling profound and lasting impact3. Even patients previously exposed to advanced treatments like CAR-T therapy showed high response rates3. The safety profile was consistent with individual drug reports, with manageable side effects and low discontinuation rates3.
"Our first-in-class bispecific antibodies TALVEY and TECVAYLI have transformed treatment for relapsed or refractory multiple myeloma," said Dr. Jordan Schecter, Vice President at Johnson & Johnson Innovative Medicine. "The RedirecTT-1 study underscores our commitment to advancing innovative therapies that attack the disease in different ways."3 This breakthrough offers a beacon of hope, potentially heralding a new era for patients who had few places left to turn.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.